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Introduction: Evans syndrome is a rare hematological disease commonly defined as Coombs-positive hemolytic
anemia and immune thrombocytopenia. Pathophysiology of this disease involves decreased cluster of differenti-
ation (CD)4+ T-helper cell counts, increased CD8+ T-suppressor cell counts, a decreased CD4/CD8 ratio, and re-
duced serum immunoglobulin G, M and A levels - indicating a complex immune dysregulation. Association with
other autoimmune diseases has been described although involvement of the central nervous system has not been
reported so far.
Case presentation: We here present a case of a 28-year-old woman of Turkish origin with progressive, dissemi-
nated, partly mass-forming lymphoplasmacellular infiltration (CD3+ and CD138+ cells) of the brain in association
with Evans syndrome. No other central nervous system disorder could be identified on neuropathological evalu-
ation. Although treatment with rituximab was effective to normalize erythrocyte and thrombocyte levels in her
peripheral blood, it failed to dampen the inflammation in her central nervous system or prevent clinical progression.
Initiation of treatment with cyclophosphamide resulted in stabilization of her central nervous system inflammation
and the disease course.
Conclusions: The complex immune dysregulation resulting in the antibody-mediated pathologies that can be
regarded as the cause of both lymphoplasmacellular encephalitis and Evans syndrome renders this association to
be of clinical relevance for both neurologists and hematologists. Our experience also sheds light on the effective-
ness of different treatments for both disorders and we advise clinicians to take a closer look when encountering a
combination of peripheral blood diseases with affection of the central nervous system.
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Evans syndrome (ES) is a rare hematological disease
commonly defined by the combination of simultaneous or
sequential autoimmune hemolytic anemia (AIHA) and im-
mune thrombocytopenia (ITP) sometimes associated with
neutropenia in the absence of known underlying etiology.
Robert Evans first described this syndrome in 1951, when
he presented evidence for a spectrum-like relationship
between acquired hemolytic anemia and primary thrombo-
cytopenic purpura [1]. Nearly all presented studies so far* Correspondence: sven.meuth@ukmuenster.de
1Department of Neurology, University of Muenster, Muenster, Germany
Full list of author information is available at the end of the article
© 2013 Simon et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhave involved small numbers of patients, and interpretation
of the results is made more difficult by the recent
recognition that some cases of ES may instead have been
autoimmune cytopenias secondary to autoimmune lym-
phoproliferative syndrome [2]. Whereas ES relies on
antibody-mediated autoimmune hemolytic anemia and
immune thrombocytopenia, the combination of AIHA
and ITP can also be observed in patients with systemic
lupus erythematosus, suggesting a link to other inflamma-
tory mechanisms [3]. In addition, not all authors adhere to
the strict definition of ES and include all patients with the
combination of ITP and AIHA, irrespective of the
etiology. However, summarizing all studies dealing withLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cellular and humoral immunity in the etiology of the
disease.
Persistently decreased cluster of differentiation (CD)4/
CD8 ratio in peripheral blood resulting from reduced
CD4+ and increased CD8+ T cell levels has been de-
scribed in six affected children compared to healthy
controls and patients with chronic ITP [4]. These
findings were corroborated in a 12-year-old patient with
ES [5], in whom the reduced CD4/CD8 ratio persisted
after splenectomy. In the same patient, an analysis of
cytokine secretion before splenectomy revealed spon-
taneous T helper cell 1-type and T helper cell 2-type
cytokine production and complete suppression of trans-
forming growth factor β. After splenectomy, the patient
had normalized levels of interleukin-2, interleukin-4,
interleukin-10, transforming growth factor β and inter-
feron γ, accompanied by clinical remission and in-
creased numbers of natural killer cells. Of note, their
patient received danazol (a derivative of the synthetic
steroid ethisterone, a modified testosterone, also known
as 17-alpha-ethinyl testosterone) before and after splen-
ectomy. The effects of this substance on reported im-
mune parameters cannot be excluded. Based on these
findings, the authors hypothesized that spontaneous se-
cretion of T helper cell 1-type cytokines (for example,
IFN-γ) could explain the activation of autoreactive B-
cells, which produce antibodies against red blood cells
and platelets.
Although these results supported other studies dem-
onstrating reduced serum immunoglobulin (Ig)G, IgM
and IgA levels in patients with ES, pointing towards
dysregulated cellular und humoral immunity [4], the
significance of these abnormalities is uncertain as they
also occur in other autoimmune conditions and in asso-
ciation with viral infection. Association with different
autoimmune diseases, such as systemic lupus erythemato-
sus [3], autoimmune hepatitis [6], Hashimoto’s thyroiditis
[7], dermatomyositis [8] and chronic inflammatory demye-
linating polyneuropathy [9], has also been described. We
here present the case of a patient with ES in combination
with dysregulation of autoimmune networks, resulting in
central nervous system damage. To the best of our know-
ledge, such an association has not yet been reported.
Case presentation
In 1999, a 14-year old girl of Turkish origin presented
with vertigo and generalized tonic-clonic seizures.
Magnetic resonance imaging (MRI) analyses showed
multiple hyperintense lesions in T2-weighted images
(bi-hemispheric periventricular white matter, frontal
cortex, left insular cortex, left brainstem). A symptom-
atic treatment with valproate was initiated. In 2002,
three years after onset of central nervous system (CNS)inflammation, a mild thrombocytopenia (110 × 103 cells/
μL) occurred for the first time, but no further diagnostics
were carried out. In the next years, she experienced various
neurological symptoms such as hypoesthesia, weakness of
her right arm, vertigo and double vision. These relapses
occurred in a frequency of one to six events per year. MRI
analyses showed a slow progression of inflammatory
gadolinium-enhancing (Gd+) lesions, mostly localized
in subcortical and periventricular areas (Figure 1).
Conventional angiographies (2004 and 2008) revealed
no signs of vessel stenosis, sinus thrombosis or other
signs indicative of primary CNS vasculitis. Under the
assumption of a relapsing-remitting multiple sclerosis,
these clinical symptoms as well as future ‘relapses’
were treated with intravenous steroids until 2011.
Initiation of immune prophylactic immunomodulatory
therapy was refused by our patient until 2008. In this
year, immune modulatory treatment with glatiramer
acetate was initiated, but was terminated by the patient
after two weeks because of needle phobia. In 2009, the
patient presented with additional anemia. After detec-
tion of warm agglutinins and a positive Coombs test, a
diagnosis of ES was established. To exclude differential
diagnoses, antinuclear antibodies, double-stranded DNA
and rheumatoid factor were analyzed. Low serum levels
of IgG and IgA allowed a retrospective diagnosis of
common variable immunodeficiency, a condition often
occurring in combination with ES [10]. Investigation
of peripheral blood T cell subsets (CD4-/CD8-, CD3+,
T-cell receptor αβ+) by flow cytometry was used to
differentiate from autoimmune lymphoproliferative syn-
drome [2]. Treatment was initiated with oral adminis-
tered corticosteroids and azathioprine. The latter needed
to be stopped due to elevated liver enzymes (Figure 2).
After our patient’s first presentation to the clinic in
2011, an extensive clinical re-evaluation was performed
due to increasing doubts concerning the initial diagnosis
of multiple sclerosis. Analyses of cerebrospinal fluid
(CSF) showed lymphocytic pleocytosis, intrathecal syn-
thesis of IgG and IgM, impairment of blood-brain-
barrier integrity and positive oligoclonal bands (June
2011: 52cells/μL, 44lymphocytes/μL, 1110mg/L protein,
10 oligoclonal bands (8 isolated in the CSF), 73.52%
CD4+ T cells (normal 73.84 ±9.48%), 6.80% CD8+ T cells
(normal 22.40 ±9.29%), CD4/CD8 ratio 10.9 (normal
3.81 ±1.52), 11.87% CD19+ B cells (normal 0.79 ±0.79%),
0.24% plasma cells (normal 0.042 ±0.042%)). A synopsis
of results of clinical chemistry and CSF analysis during
the time course is shown in Table 1.
In 2011, 16 lesions were evident on T2-weighted and
fluid-attenuated inversion recovery images, with three
new Gd + lesions localized in her right cerebellar hemi-
sphere, right frontobasal region and right frontal cortex.
Measurements of visual, sensory and motor evoked
Figure 1 Magnetic resonance imaging time course of the patient during different stages of treatment. Fluid-attenuated inversion recovery
and T1-weighted with gadolinium (exemplary images are shown). Arrows indicate gadolinium-enhancing lesions. Treatment with cyclophospha-
mide resulted in stable disease without new contrast enhancing lesions. FLAIR, fluid-attenuated inversion recovery; Gd, gadolinium.
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nostic, including serological, microbiological and viro-
logical analyses from both her blood and CSF, revealed
no signs for a systematic vasculitis, infection or any
underlying specific autoimmune diseases. After another
relapse presenting with unsystematic vertigo, we ultim-
ately clarified the nature of her inflammatory leukoence-
phalopathy by performing a brain biopsy. This showed
severe perivascular inflammatory infiltrates as well as
diffuse cellular infiltration within the parenchyma. The
infiltrates were dominated by small mature CD3+ T cells
and high numbers of CD138+ plasma cells (Figure 3)
whereas only low B-cell numbers could be observed.Figure 2 Timeline of treatment. AZA, azathioprine; GA, glatiramer
acetate; GCS, glucocorticosteroids intravenous or orally; RTX,
rituximab; CYC, cyclophosphamide.Plasma cells expressed lambda and kappa light chains.
The proliferative index was between 5% and 7%.
Immunohistochemical stainings for different patho-
gens (herpes simplex virus 1 and 2, Epstein-Barr virus,
JC virus and toxoplasma) were negative. Additional
stainings revealed no signs of demyelination, vasculitis
or a brain-derived neoplasia.
A diagnosis of lymphoplasmacellular encephalitis was
made; inflammatory demyelinating disorders, vasculitis,
neoplasias or infections were excluded. Based on the de-
tection of CD20+ B cells and CD138+ plasma cells both
by flow cytometry assessment of her CSF and by immu-
nohistochemical stainings, we initiated treatment with
anti-CD20 monoclonal antibody rituximab. This treat-
ment regimen could be beneficially used in CNS inflam-
mation and has already been reported to be effective in
cases of ES [11,12]. Treatment was effective in terms of
peripheral B cell depletion and led to the stabilization of
her blood cell counts (Figure 4, Table 1). Despite the
ongoing peripheral depletion of B cells, our patient
developed new symptoms and two new Gd +MRI
lesions eight months after starting treatment (April 2012;
Figure 1). CSF analysis still showed elevated cell counts
and normal protein levels (13cells/μL, 13 lymphocytes/μL,
Table 1 Laboratory results from peripheral blood and cerebrospinal fluid during treatment
Peripheral blood Normal range Oct 2009 Jun 2011 Aug 2011 Nov 2011 Apr 2012 Sep 2012 Oct 2012
Thrombocytes (103/μL) 150 to 390 73.00 101.00 62.00 165.00 195.00 171.00 178.00
Erythrocytes (106/μL) 3.92 to 5.08 1.43 4.36 4.44 4.74 4.88 4.38 4.18
Leucocytes (103/μL) 4.49 to 2.68 7.51 4.71 5.74 5.00 6.42 4.60 4.35
Lymphocytes (103/μL) 1.2 to 3.0 800.00 594.00 426.00 592.00
CD3+ (103/μL) 0,8 to 1,2 1,049 0,475 0,300 0,601
CD4+ (%) 29 to 59 35.31 43.00 36.90 41.40
CD8+ (%) 19 to 48 34.13 31.00 31.30 54.25
CD4/CD8 ratio 0.7 to 2.8 1.03 1.40 1.20 0.76
CD19+ (103/μL) 0,1 to 0,8 0,144 0.00 0.00 0,04 0.00
Hemoglobin 12 to 16 [g/dL] 6.60 13.90 13.00 13.40 14.40 13.40 13.00
IgG (g/L) 7 to 16 3.20 4.41 0.98
IgA (g/L) 0.7 to 3.8 0.10 0.05 0.04
IgM (g/L) 0.4 to 2.8 0.90 0.20 0.14
Glucose (mg/L) 70 to 120 92.70 88.10 97.30
Albumin (g/L) 35 to 55 46.30 41.90 39.70
Oligoclonal bands <3 2.00 1.00 1.00
Cerebrospinal fluid Normal range Oct 2009 Jun 2011 Aug 2011 Nov 2011 Apr 2012 Sept 2012 Oct 2012
Lymphocytes (/μL) <4 44.00 13.00 1.00
CD3+ (%) 79.67 to 95.03 83.71 94.32 55.06
CD4+ (%) 64.36 to 83.32 73.52 87.97 65.52
CD8+ (%) 13.11 to 31.69 6.80 8.82 34.48
CD4+ CD8+ (%) 0.55 to 2.91 0.44 0.57 1.15
CD4/CD8 ratio 2.29 to 5.33 10.79 9.94 1.67
CD4+ HLA DR + (%) 2.71 to 9.71 10.69 14.67 5.55
CD8+ HLA DR + (%) 15.74-25.60 16.12 50.59 44.83
CD19+ % (%) 0 to 1.58 11.87 3.52 5.06
CD19+ CD138+ (%) 0 to 0.107 0.24 0.10 0.00
Lactate (mmol/L) >2.1 1.05 1.28 1.39
IgG (mg/L) <40 65.40 4.50 3.34
IgM (mg/L) <1 4.30 1.41 0.25
IgA (mg/L) <6 2.10 12.70 1.13
Glucose (mg/dL) 60 to 85 35.80 53.60 49.20
Protein (mg/L) 150 to 450 1.100.00 254.00 169.00
Albumin (mg/L) 100 to 300 539.00 157.00 116.00
Oligoclonal bands <3 10.00 6.00 0.00
CD cluster of differentiation, Ig immunoglobulin.
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isolated oligoclonal bands, 87.97% CD4+ T cells, 0.57%
CD8+ T cells, CD4/CD8 ratio 9.94, 3.5% B cells, 0.1%
plasma cells; for details see Table 1). Although treatment
with rituximab was effective in her ‘periphery’, it was not
able to fully reduce B- and plasma cell counts in the CNS
as reflected by CSF analysis (Figure 4). Therefore, we initi-
ated treatment with cyclophosphamide at a dosage of
350mg/m2 on three consecutive days, followed by monthlyintravenous applications of 600 to 750mg/m2, adapted to
leukocyte levels. Cyclophosphamide is an alkylating im-
munosuppressant widely used for the treatment of cerebral
vasculitis. Over 12 months of follow-up, this therapy has
maintained a stable disease course and MRI findings.
Conclusions
Patients with ES often benefit from treatment with corti-
costeroids, but they frequently experience hematological
Figure 3 Immunohistology of brain biopsy. Example images show infiltration of T cells (CD3) and plasma cells (CD138), respectively. CD,
cluster of differentiation.
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nosuppressants, among them methotrexate and myco-
phenolate mofetil. Splenectomy is another option in
steroid-refractory or relapsing courses. There have been
recent publications of cases treated with rituximab
[6,11,13], which showed promising clinical effects.
Rituximab is a monoclonal antibody directed against
CD20 on B lymphocytes that leads to a reduction of B
cells in the peripheral blood as well as putatively in the
CSF [14]. The efficiency of an anti-CD20 therapeutic
strategy further reinforces the concept of plasma cell-
originated antibodies as a major pathophysiological
mechanism of ES.
ES, thought of as a disease caused by immune dysreg-
ulation, has been associated with different autoimmune
diseases such as systemic lupus erythematosus [3], derm-
atomyositis [8] and many others. To the best of our
knowledge, an association with autoimmune mediated
CNS inflammation has not been described so far. One
case of an infant with ES associated with a polyclonalFigure 4 Parameters of cerebrospinal fluid and peripheral
blood during treatment.lymphoproliferative disease and subsequent parenchymal
CNS lesions has been published [15]. Our case suggests
a common underlying pathophysiology of both diseases
(lymphoplasmacellular encephalitis and ES), mediated by
antibodies derived from peripheral or CNS-infiltrating
plasma cells, respectively. In the case we present here,
progressive lymphoplasmacellular infiltrations of her
CNS, resulting in multiple inflammatory lesions without
demyelination or signs of a lymphoma or neoplasia, pre-
ceded the manifestation of ES. Our extensive differential
diagnostic workup was not able to elucidate any under-
lying pathology for both diseases. The histological find-
ings from a brain biopsy could not be ascribed to any
other defined inflammatory CNS disease.
Although it is not possible to prove a direct link
between lymphoplasmacellular encephalitis and ES, it
seems likely since both diseases are based on complex
immune dysregulation in the periphery and/or in the
CNS. One can argue that peripheral dysregulation of im-
mune responses, which leads to self-reactive antibodies
directed against peripheral blood cells on the one hand
and neuronal antigens on the other hand, can result in
both peripheral and central manifestations and therefore
represents a link for both diseases. It is therefore benefi-
cial to conduct a complete neurological assessment in-
cluding MRI and CSF examination in cases of patients
with ES presenting with neurological symptoms, in par-
ticular cortical and cognitive manifestation. Dysfunction
of the immune system can be observed in patients with
ES in terms of peripheral CD4/CD8 alterations. In this
case, we also observed an unusual disturbance of CD4/
CD8 ratio in the CSF. Treatment with the B-cell-
depleting antibody rituximab was able to stabilize the
peripheral part of the disease while her intrathecal
immune reaction was only partially reduced in terms of
CD19+, CD4+, CD8+, CD4+ human leukocyte antigen
DR+ and CD8+human leukocyte antigen+ cell counts.
Treatment with cyclophosphamide further reduced these
parameters, parallel to improved MRI findings and
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support the notion that treatment with rituximab might
in some cases be less effective for suppression of CNS
inflammation compared to treatment strategies with
cyclophosphamide.
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